Press Releases Zura Bio Limited

Equities

ZURA

KYG9TY5A1016

Real-time Estimate Cboe BZX Other stock markets 12:30:45 2024-05-17 pm EDT			5-day change	1st Jan Change
6.185 ^USD	+19.17%		+12.83%	+11.13%

May. 10	Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating	MT
May. 09	Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 09	BU
Zura Bio Announces Oversubscribed $112.5 Million Private Placement	Apr. 18	BU
Zura Bio Announces Robert Lisicki as CEO and Director	Apr. 08	BU
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer	Mar. 28	BU
Zura Bio Announces Participation at March Conferences	Mar. 04	BU
Zura Bio Announces Participation at February Investor Conferences	Feb. 02	BU
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO	Jan. 08	BU
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit	Jan. 03	BU
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok	Dec. 04	BU
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors	Nov. 14	BU
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights	Nov. 13	BU
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute	23-09-12	BU
Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights	23-08-14	BU
Zura Bio to Join the Russell 2000® and Russell 3000® Indexes	23-06-23	BU
Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist	23-06-06	BU
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab, a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases	23-04-28	AQ
Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases	23-04-27	BU
Zura Bio Announces Appointment of Chief Scientific Officer	23-04-17	AQ
Zura Bio Announces Appointment of Chief Scientific Officer	23-04-14	BU
Zura Bio Limited Announces Share Redemptions and Lock-up Agreement	23-03-27	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Zura Bio Limited

Equities

ZURA

KYG9TY5A1016

Press Releases

Filters